Skip to main content

Welcome to the Circle Health Group website. We've changed our name from BMI Healthcare. Just as before, we have thousands of specialists offering expert healthcare. Click here to find a specialist or a hospital near you.

Mr Luis Aznar-Garcia

Consultant Oncologist


Practices at: The Park Hospital

A photo of Mr Luis Aznar-Garcia

Personal Profile

Luis Aznar-Garcia is a Consultant Clinical Oncologist at The Park Hospital and is also currently working at the Nottingham University Hospitals as a Stereotactic Radiosurgery (SRS) and Brain Metastases MDT Lead Clinician. He is also involved in Stereotactic Ablative Radiotherapy (SABR/SBRT) for Oligometastases, Hepatobilliary (HpB) tumours and breast cancer.

Luis Aznar-Garcia has broad experience in the field of highly advanced radiotherapy treatments. His main expertise is in the area of the Stereotactic Radiotherapy (SRS and SABR/SBRT), with a vast professional experience using Gammknife, Cyberknife, Magnetic Resonance Image Guided Radiotherapy (MRL) and Linac-based platforms to treat metastatic disease as well as primary tumours. He has treated more than 1000 patients with Stereotactic techniques since 2001.

Luis Aznar-Garcia has been Head of the Radiotherapy Department at Leicester University Hospitals for 3 years and Head of Radiotherapy and Radiosurgery at Ruber International Hospital (Madrid, Spain) for 2 years. He has been a Clinical Oncologist Consultant for more than 20 years.

He is an Honorary (Consultant) Assistant Professor at The University of Nottingham.

He is also a member of multiple National and International Oncological Societies (ESTRO, ISRS, ESMO, RCR, SEOR…).

Mr Aznar-Garcia is an Editor of several International Oncological Journals, and has published around 37 papers in International Medical Journals, books and meeting presentations.

He is an Investigator in several Stereotactic Radiotherapy Trials (CORE, ABC-07, OligoRare, SARON, HALT, SPARC, SCALOP 2), some of them as Principal Investigator.

In addition, he has had a successful application to Genome England Clinical Interpretation Partnership (GeCIP).